Results 21 to 30 of about 871,553 (293)

Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies

mBio
Antibodies targeting an envelope dimer epitope (EDE) cross-neutralize Zika virus (ZIKV) and dengue virus (DENV) and have thus inspired an epitope-focused vaccine design. There are two EDE antibody subclasses (EDE1, EDE2) distinguished by their dependence
Maya Contreras, Jackson B. Stuart, Lisa M. Levoir, Laura Belmont, Leslie Goo   +4 more
doaj   +2 more sources

Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1 [PDF]

Advanced Science
Broadly neutralizing antibodies are proposed as therapeutic and prophylactic agents against HIV‐1, but their potency and breadth are less than optimal.
Jianliang Xu, Tongqing Zhou, Krisha McKee, Baoshan Zhang, Cuiping Liu, Alexandra F. Nazzari, Amarendra Pegu, Chen‐Hsiang Shen, Jordan E. Becker, Michael F. Bender, Payton Chan, Anita Changela, Ridhi Chaudhary, Xuejun Chen, Tal Einav, Young Do Kwon, Bob C. Lin, Mark K. Louder, Jonah S. Merriam, Nicholas C. Morano, Sijy O'Dell, Adam S. Olia, Reda Rawi, Ryan S. Roark, Tyler Stephens, I‐Ting Teng, Emily Tourtellott‐Fogt, Shuishu Wang, Eun Sung Yang, Lawrence Shapiro, Yaroslav Tsybovsky, Nicole A. Doria‐Rose, Rafael Casellas, Peter D. Kwong   +33 more
doaj   +2 more sources

Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies.

PLoS Pathogens, 2019
Recently identified broadly neutralizing antibodies (bnAbs) show great potential for clinical interventions against HIV-1 infection. However, resistant strains may impose substantial challenges.
Panpan Zhou, Han Wang, Mengqi Fang, Yangyang Li, Hua Wang, Shasha Shi, Zihao Li, Jiapeng Wu, Xiaoxu Han, Xuanling Shi, Hong Shang, Tongqing Zhou, Linqi Zhang   +12 more
doaj   +2 more sources

Cervicovaginal microbiome diversity was not associated with mucosal pharmacokinetics of systemically delivered HIV broadly neutralizing antibodies. [PDF]

Sci Rep
Broadly neutralizing antibodies (bNAbs) are a promising HIV prevention strategy due to their potent antiviral activity and potential for long-acting protection.
Mtshali A, Togo AH, Kama A, Letsoalo M, Mzobe G, Sivro A, Garrett N, Zondo N, Mahomed S, Archary D, Ngcapu S.   +10 more
europepmc   +2 more sources

Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1

Antibodies, 2022
Monoclonal antibodies have been used successfully as recombinant protein therapy; however, for HIV, multiple broadly neutralizing antibodies may be necessary.
Elisabeth Narayanan, Samantha Falcone, Sayda M. Elbashir, Husain Attarwala, Kimberly Hassett, Michael S. Seaman, Andrea Carfi, Sunny Himansu   +7 more
doaj   +1 more source

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. [PDF]

PLoS Pathogens, 2013
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine.
Constantinos Kurt Wibmer, Jinal N Bhiman, Elin S Gray, Nancy Tumba, Salim S Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore   +7 more
doaj   +1 more source

Broadly neutralizing monoclonal antibodies for HIV prevention [PDF]

Journal of the International AIDS Society, 2021
AbstractIntroductionThe last 12 years have seen remarkable progress in the isolation and characterization of at least five different epitope classes of HIV‐specific broadly neutralizing antibodies (bnAbs). Detailed analyses of these bnAb lineages, maturation pathways and epitopes have created new opportunities for vaccine development.
Maurine D. Miner, Lawrence Corey, David Montefiori   +2 more
openaire   +2 more sources

HIV broadly neutralizing antibody targets [PDF]

Current Opinion in HIV and AIDS, 2015
To provide an update on neutralizing antibody targets in the context of the recent HIV-1 envelope trimer structure, describe new antibody isolation technologies, and discuss the implications of these data for HIV-1 prevention and therapy.Recent advances in B-cell technologies have dramatically expanded the number of antibodies isolated from HIV ...
Constantinos Kurt, Wibmer, Penny L, Moore, Lynn, Morris   +2 more
openaire   +2 more sources

The Mechanism of bnAb Production and Its Application in Mutable Virus Broad-Spectrum Vaccines: Inspiration from HIV-1 Broad Neutralization Research

Vaccines, 2023
Elite controllers among HIV-1-infected individuals have demonstrated a stronger ability to control the viral load in their bodies. Scientists have isolated antibodies with strong neutralizing ability from these individuals, which can neutralize HIV-1 ...
Xinyu Zhang, Zehua Zhou
doaj   +1 more source

Correlates of broadly neutralizing antibody development [PDF]

Current Opinion in HIV and AIDS, 2019
PURPOSE OF REVIEW Broadly neutralizing antibodies (bnAbs) are considered a key component of an effective HIV-1 vaccine, but despite intensive efforts, induction of bnAbs by vaccination has thus far not been possible. Potent bnAb activity is rare in natural infection and a deeper understanding of factors that promote or limit bnAb evolution is critical ...
Abela, Irene A, Kadelka, Claus, Trkola, Alexandra   +2 more
openaire   +3 more sources